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Antibodies to Core Lipopolysaccharide Determinants: Absence of
Cross-reactivity with Heterologous Lipopolysaccharides
D. Heumann, J. D. Baumgartner,
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Using monoclonal antibodies directed against defined epitopes of endotoxin core, this study
demonstrated that the presentation of lipopolysaccharide (LPS) to antibodies is critical for mea-
suring the specific binding of antibodies to LPS structures. False cross-reactive reactions appar-
ently were observed when free core LPS or lipid A were used as antigens in ELISA, whereas
coating with complexes of high-density lipoproteins with core LPS increased both the sensitivity
and the specificity of the test compared with coating with free core LPS, so that nonspecific bind-
ing of antibodies was largely avoided. Using this technique, it was not possible to find broadly
cross-reactive core LPS antibodies after immunization of rabbits and humans with rough mu-
tants of gram-negative bacteria. These observations underscore the need for careful evaluation
of the potential for cross-reactivity of antisera and of monoclonal antibodies directed against
endotoxin core.
The core region of lipopolysaccharides (LPS) is relatively
similar in structure among various gram-negative bacteria,
whereas the outermost a-side chains are responsible for the
marked antigenic diversity of gram-negative bacteria. a-side
chain-specific antibodies afford a strain-specific protection
but do not protect against heterologous strains in animal
models. The core region of LPS is exposed at the surface of
the a-side chains lacking rough mutants, among which Esch-
erichia coli J5 and Salmonella minnesota R595 have been the
most studied. After immunization with such mutants, antisera
of rabbits or humans contain antibodies directed against core
LPS. These antisera have been reported to protect against chal-
lenge with heterologous gram-negative bacteria or smooth LPS
[1-5]. However, the demonstration that protection is due to
core LPS antibodies has not been convincingly put forward
so far, especially because of the difficulty in unequivocally
demonstrating cross-reactions between core LPS antibodies
and purified LPS extracted from heterologous stationary-phase
bacteria [1, 6-13].
Investigations of the role of cross-reactive antibodies in im-
munity to endotoxins require an accurate and specific assay
for antibodies directed against the various epitopes of core
LPS and lipid A. A number of serologic tests have been pro-
posed to measure these antibodies, including immunofluores-
cence [14, 15], passive hemagglutination [3, 16-18], and
'passive hemolysis [19-23]. In recent years, core LPS anti-
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bodies have usually been measured by ELISA. Polyclonal rab-
bit antisera raised against core LPS and lipid A [9, 10, 17,
24-26], murine monoclonal hybridomas selected against core
LPS or lipid A [12, 27-30], and human sera from normal
volunteers and patients [31-34] were analyzed by this tech-
nique. These tests were done with LPS diluted in aqueous
buffers as coating antigen. However, due to the limited solu-
bility and self-aggregating properties of amphiphilic core LPS
or lipid A, this procedure might induce a poorly reliable coat-
ing of the antigen and an increase in the nonspecific binding
of immunoglobulins [23]. To immobilize antigen at the bot-
tom of the wells, some techniques have relied on a chemical
treatment before coating, which may modify or delete epi-
topes. Another proposed method has been to use core LPS
and lipid A in association with bovine serum albumin to im-
prove the coating [35-37].
In the present study, we investigatedvarious EUSA methods
for demonstrating cross-reactive antibodies against endotoxin
core. To obviate the potential nonspecific binding of antibod-
ies to the hydrophobic structures of LPS, we complexed LPS
with high-density lipoproteins (HDL), a natural carrier in vivo
of LPS both in animals and humans [38, 39]. The use of com-
plexes of LPS or lipid A with HDL has three theoretical ad-
vantages: (1) a better coating of the plastic due to the protein
carrier effect, (2) a removal of LPS contaminants (e.g., pro-
teins and nucleic acids) during the ultracentrifugation step
used to purify LPS-HDL complexes, and (3) a more physio-
logic presentation of the antigen since LPS is rapidly com-
plexed with HDL in the circulation [38, 39].
We compared the binding of antibodies to LPS-HDL com-
plexes with the binding to free LPS or lipid A. We used mono-
clonal antibodies directed against precisely defined epitopes
of core LPS to determine the accuracy of the binding observed
with the various antigen preparations. Finally, using the vari-
ous ELISA techniques, we investigated the development of
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cross-reactive antibodies after immunization of animals and
humans with E. coli J5.
Material and Methods
LPSandbacteria. E. coli0111:B4, E. coli15, S. minnesotaS128
and its rough mutants were gifts from E. J. Ziegler (San Diego).
LPS from E. coli 0111:B4 (0111 LPS) was obtained from Sigma
Chemical (St. Louis). LPS from E. coli 15 mutant (15 LPS), LPS
from S. minnesota R595 mutant (Re LPS), and lipid A from S. min-
nesota R595 mutant (lipid A) were obtained from Ribi Immunochem
Research (Hamilton, MT). Lyophilized powders were reconstituted
at a concentration of 1 mg/ml in pyrogen-free water, with 0.5 %
(vol/vol) triethylamine for Re LPS and lipid A. For preparation of
radiolabeled LPS, E. coli 0111:B4 and E. coli15were grown in tryp-
ticase soy broth containing 10 mCi pH]acetate/l, and LPS was
extracted by the water-phenol method [40]. PH]LPS from S. min-
nesota R595 was a gift from R. I Ulevitch (San Diego). Lipid A
(0.5 mg; Ribi) was labeled with 100 JLCi 51Cr [41].
Immunizations. Boiled E. coli 0111:B4 and E. coli J5 bacterial
cells were suspended in 0.15M NaCI and adjusted spectrophotometri-
cally to a concentration of 5 X 109 cells/ml (22% light transmis-
sion at 610 nm). New Zealand rabbits were immunized with six
intravenous injections of 1 ml of boiled cells administered during
a 2-week period. Samples of serum were collected 7 days after the
last injection. Lipid A and Re LPS vaccines were prepared by react-
ing 10 ml of sheep red blood cells with 5 ml of lipid A or Re LPS
at 1 mg/mI. After extensive washing in NaCI (0.9 %), 0.5 ml of sen-
sitized sheep red blood cells were given intravenously three times
per week for 2 weeks and the postimmunization serum was obtained
7 days after the last injection. Healthy human volunteers were im-
munized with 15 vaccine (provided by E. J. Ziegler) as described
[4, 5].
Monoclonal antibodies. Mouse monoclonal antibody C117
(IgG2b), a gift from B. J. Appelmelk (Amsterdam) was obtained
by immunizing mice with S. minnesota R595 [42]. It recognizes an
epitope consisting of parts of the 3-deoxY-D-manno-2-octulosonic
acid (KDO) disaccharide and lipid A; it is specific for Re LPS but
specificity for lipid A alone is absent [43]. Clones SAl (IgGl) and
lC3 (lgG3, an isotype switch variant of8A1 with the same specificity),
developed by Centocor (Malvern, PA), were provided by Hoffmann-
La Roche (Basel, Switzerland); they were from immunizations of
mice with heat-killed E. coli J5 boosted with a mixture of 15 LPS
and Re LPS. Both of the latter monoclonal antibodies are directed
against a yet undefined epitope within the lipid A structure [29, 30].
The two human IgM hybridomas F117 and F136 were obtained by
one of us (H. I-G.) from fusions of a human heteromyeloma cell
line with peripheral blood lymphocytes of human volunteers vacci-
nated with heat-killed E. coli 15 bacteria. F117 is directed against
a yet undefined epitope of the lipid A, and F136 exclusively recog-
nizes the J5 LPS core, as revealed by immunoblotting techniques.
Affinitypurification ofhumanJ5LPSantibodies. Plasma obtained
from human volunteers immunized with heat-killed E. coli J5 bac-
teria [5] were screened by ELISA, selected for high titer of antibody
against15 LPS, and pooled. A high-titered pool wasused for purifica-
tion of immunoglobulins. After enrichment of immunoglobulins by
precipitation of the pool with saturated (Nl4hS04 at a final con-
centration of 50 %, crude fractions enriched in IgM or IgG were
obtained by gel filtration through Bio-gel A (1.5m; Bio-Rad Labora-
tories, Richmond, CA) equilibrated in 20 mMphosphate buffer, 150
mMNaCI, pH 7.3 (PBS). Absence of the other immunoglobulin was
checked in both fractions, using Ouchterlony plates developed with
precipitating commercial anti-human IgG or IgM antisera (Cappel
Laboratories, Malvern, PA). The IgG-enriched fraction was furth'er
purified by affinity adsorption on protein-A sepharose (Pharmacia,
Uppsala, Sweden), resulting in a homogenous population of IgG
devoid of IgM, as revealed both by Ouchterlony analysis and SDS-
PAGE. The IgM-enriched fraction was further passed through a sec-
ond gel filtration column, using Sepharose CI-2B (Pharmacia)
equilibrated in PBS to remove high-molecular-weight contaminants,
and finally purified by ion-exchange chromatography on DEAE-
sepharose [44] to eliminate <:Yz-macroglobulin. When developed in
Ouchterlony plates with a polyclonal anti-human IgM antiserum or
with a polyclonal anti-whole plasma antiserum, this IgM prepara-
tion gave one single line of identity, confirmed by the presence of
a single band in SDS-PAGE run in nonreduced conditions.
The final step consisted of affinitypurification using15LPS-agarose
equilibrated in PBS. The affinity resin containing J5 LPS (15 LPS-
agarose) was prepared as described [38] after activation of di-
aminodipropylamine agarose (Pierce Chemical, Rockford, IL) with
6%glutaraldehyde and coupling with purified core glycolipid in 50
mM sodium borate buffer (pH 8.2). Both purified IgG and IgM frac-
tions were passed through the affinity column; after loading, the
column was extensively washed with PBS before specific anti-LPS
antibodies were eluted with 0.1M glycine-HCIbuffer (pH 2.5). Eluted
antibodies were immediately neutralized with 1 M TRIS and dia-
lyzed against PBS. Specific antibodies were measured (JLg/mI) using
radial immunodiffusion plates prepared for detection of human IgG
or IgM (Nor Partigen, Behring, Germany).
Preparation ofLPS-HDL complexes. LPS-HDL complexes were
prepared as described [45] (except that 100 JLg of LPS/mI of plasma
was added instead of 10 JLg). Briefly, a pool of fresh human plasma
was made 20 mM in EDTA; 100 JLg aliquots of LPS or lipid A were
added for each milliliter of plasma. Incubation was done for 1 h at
37°C. LPS-HDL complexes were then isolated by ultracentrifuga-
tion with increasing concentrations of potassium bromide (KBr),
as described for purification of HDL [46]. In this manner we pre-
pared J5 LPS-HDL, Re LPS-HDL, lipid A-HDL, and 0111 LPS-
HDL complexes and isolated normal HDL as a control for ELISA.
After ultracentrifugation in KBr, complexes were dialyzed against
75 mM TRIS/150 mM NaCI (pH 7.3) containing 0.1% EDTA and
kept at 4°C. The final volume of the solution of purified HDL or
HDL-LPS was one-fifth the initial volume of plasma used for the
extraction. The amount of LPS within HDL was quantified using
radiolabeled LPS.
EliSA. The assay was done in 96-well Immulon ELISA plates
(Dynatech Laboratories, Alexandria, VA). For coating with PBS
buffer, antigen was dissolved at 10 JLg/ml and 100 JLI aliquots were
distributed per well, incubated for 2 h at 37°C, and let stand over-
night at 4°C. With LPS-HDL complexes, 100 JLI aliquots of com-
plexes dissolved 1:200 in PBS were coated in the same way as for
native antigen in PBS. For coating in ethanol, 100 p.l aliquots of
antigen dissolved at 10 JLg/ml in ethanol were left overnight at room
temperature, allowing complete evaporation of the solvent. Aftee
antigen coating, plates were shaken empty, extensively washed with
PBS, and remaining antigen-attachment sites were blocked by add-
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Table 2. Comparison of coating with LPS-HDL complexes or
with free LPS for measuring monoclonal antibodies against lipid
A or core LPS.
Table 1. Amount of radiolabeled lipopolysaccharide (LPS) bind-
ing to the high-density lipoprotein (HDL) fraction during the prep-
aration of LPS-HDL complexes.
NOTE. A known amount of radiolabeled LPS was added to EDTA plasma, and
the total cpm was measured in plasma. The LPS-HDLcomplexes were then extracted
[45]. Total cpm in LPS-HDL fractions was measured and the percentage recovered





Complex (ug/ml) Plasma fraction recovered
J5 [3H]LPS 10 7425 4070 55
100 77,230 43,200 56
Re PH]LPS 100 75,000 59,220 79
0111 PH]LPS 100 32,500 15,980 50
[SICr] lipid A 20 15,680 13,330 85





ing 10% fetal calf serum in PBS (PBS-PCS) and incubating for 90
min at 37°C. After additional PBS washings, 100 IIIoftest sera diluted
in PBS-PCS were added in triplicate and incubation proceeded for
2 h at 37°C. The plates were again washed thoroughly with PBS
and incubated for 75 min with a 1:1000 dilution in PBS-PCS of
horseradish-peroxidase conjugates of various specificity: These in-
cluded goat antibodies specific for human 'Y or Il chain (Sigma), goat
antibodies specific for rabbit 'Y chain (Sigma) or rabbit Il chain (Cap-
pel), and goat antibodies specific for mouse 'Y chain (Sigma). After
extensive washing with PBS, substrate (50 mg a-phenylenediamine,
20 III H202 30% (vol/vol) in 60 ml of 50 mM citrate buffer, pH 5.5)
was added. Enzymatic reaction at room temperature was stopped
with 40 III H2S04 4 N after various periods, depending on the
intensity of reaction. The A490 was measured using a Dynatech
MR600 photometer (Dynatech, Chantilly, VA).
After initial studies to determine the optimal conditions of coat-
ing, a concentration of 10 Ilg/ml of free antigens in PBS or ethanol
or a dilution of 1:200 of the solution of LPS-HDL in PBS (i.e., 1-2
Ilg/ml LPS) was adopted. Controls were included using HDL alone
as a solid-phase coating when ELISA was run with LPS-HDL com-
plexes or using buffer or ethanol for the other two techniques. Usu-
ally background values ranged between 0.02 to 0.2 A490, with
slightly higher background values with HDL than with the other two
techniques. Control values were subtracted from total readings.
Results
Demonstration ofLPS within LPS-HDL complexes. Plas-
ma (3 ml) containing various concentrations of radiolabeled
LPS were processed for isolating LPS-HDL complexes. Ta-
ble 1 shows that 50%-85% of the radioactivity was recov-
ered within the HDL fraction. The final volume of LPS-HDL
complexes was one-fifth the initial plasma volume. Since we
used an initial concentration of 100 ~g/ml LPS in plasma for
preparing the LPS-HDL complexes for ELISA, the concen-
tration of LPS within the complexes wa~s between 250 ~g/ml
for 0111 LPS-HDL and 425 ~g/ml for lipid A-HDL. When
preparing the plates for ELISA, the complexes were diluted
1:200, corresponding to a final concentration of rvl-2 ~glml.
HDL alone had a pattern identical to that of LPS-HDL com-
plexes after protein staining of samples run in SDS-PAGE.
The major protein was apoprotein AI. There was a small band
of albumin (data not shown).
Studies with monoclonal antibodies (table 2). Cross-re-
actions outside the expected specificity were obtained with
monoclonal antibodies when ELISAs were done using free
LPS either in PBS or in ethanol solvent for coating. The ap-
parent cross-reactivity observed in these conditions was prob-
ably an artifact, since C11? was found to bind to lipid A,
whereas it has no specificity for lipid A alone. A similar, prob-
ably misleading, cross-reactivity was seen with monoclonal
antibody F136, an antibody specific for J5 LPS core sugars;
it bound to lipid A, a molecule lacking core sugars. That these
findings may be associated with the physicochemical state of
LPS is suggested by the observation that the roughest LPS
had the strongest apparent cross-reaction; in contrast, non-
Re LPS Lipid A Lipid A J5 LPS Lipid A
Antigen C1l7 8AI lC3 F136 F1l7
HDL-J5 LPS 0 0 0 >2 0
HDL-Re LPS 1.98 0 0 0 0.11
HDL-lipid A 0 1.67 1.95 0.11 1.16
HDL-0111 LPS 0 0 0 0 0
J5 LPS* 0.15 0.21 0.21 >2 0
Re LPS* 1.98 0.12 0.30 0.09 0
Lipid A* 0.57 >2 >2 0.20 1.57
0111 LPS* 0 0 0 0 0
J5 LPSt 0.55 0.53 0.52 >2 0.74
Re LPSt 1.84 0.86 0.82 1.04 1.74
Lipid At 1.60 >2 >2 1.16 >2
0111 LPSt 0 0 0 0 0.33
NOTE. Values are shown as optical densities (aD) obtained under these condi-
tions: monoclonalantibody concentration, -0.5 ug/ml; dilution of conjugated anti-
body, I: 1000; incubationof peroxidase substrate, 6 min. Results are expressed after
subtraction of background values. Ol) values <0.05 are shown as O. LPS, lipopoly-
saccharide; HDL, high-density lipoprotein.
* Free LPS or lipid A diluted in PBS.
t Free LPS or lipid A diluted in ethanol.
specific binding was not observed when using a hydrophilic
antigen like the LPS from the smooth strain E. coli 0111.
In contrast, when ELISAs were done using LPS within HDL
complexes for coating, antibodies appeared highly specific
for the corresponding antigens. This was the case for mono-
clonal C11? directed against Re LPS, monoclonal antibodies
SAl, lC3, and Fl1? directed against lipid A, and the mono-
clonal antibody F136 recognizing J5 LPS. Cross-reactions
were nonexistent for IgG antibodies and minimal for IgM an-
tibodies.
Studies with polyclonal rabbit antisera (table 3). Using
the various antigens for coating, we evaluated the ELISA pat-
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Table 3. Comparison of coating with LPS-HDL complexes or
with free LPS for measuring antibodies against lipid A or core LPS
in rabbit sera.
Table 4. Comparison of coating with LPS-HDL complexes or
with free LPS for measuring antibodies against lipid A or core LPS
in humans.
Discussion
NOTE. Optical densities (OD) are shown after subtraction of background values
under these conditions: primary antibody diluted I :50, conjugates diluted I: 1000, in-
cubation with peroxidase substrate 20 min. OD values <0.05 are shown as O. LPS,
lipopolysaccharide; HDL, high-density lipoprotein.
* Total IgG and IgM fractionated from a pool of plasma with a high titer of anti-
bodies against J5 LPS.
t Anti-J5 LPS IgG and IgM antibodies were imrnunopurified from total IgG and
IgM fractions using a column of J5-LPS agarose.
*Free LPS or lipid A diluted in PBS buffer.
§ Free LPS or lipid A diluted in ethanol.
Antigen IgG IgM IgG IgM
HDL-J5 LPS 1.608 1.345 0.735 >2
HDL-Re LPS 0.095 0.090 0 0
HDL-lipid A 0.109 0 0 0
J5 LPS:j: 0.620 0.851 0.836 >2
Re LPS:j: 0.258 0.312 0 0.130
Lipid A:j: 0.321 0.175 0.118 0.166
J5 LPS§ 1.029 1.110 0.622 >2
Re LPS§ 0.507 0.847 0.067 0.326
Lipid A§ 0.423 1.215 0.142 0.851
The existence of a broad cross-reactivity of core LPS anti-
bodies has not been unequivocally shown so far because of
the difficulty in demonstrating in vitro that polyclonal or mono-
clonal antibodies to core LPS can bind to a variety of LPS
extracted from smooth strains [1, 6-13]. In addition, although
the structure of the core LPS or of the lipid A is more con-
served than that of the O-side chains, there is nevertheless
significant variability among strains. Recently, in a study of
29 murine monoclonal core LPS antibodies, Pollack et al.
[12] found that cross-reactivity was restricted by inter- and
intraspecies differences in covalent core structures and by epi,
tope concealment by overlying O-side chains and core sug-
ars. However, it has been argued that the LPS usually used





vaccinated with E. coli J5. In addition, each immunoglobulin
fraction was affinity-purified through J5 LPS-agarose and
tested in the various ELISA conditions. The contents of anti-
Re LPS or anti-lipid A antibodies in both total IgG or IgM
pools appeared considerably higher when free LPS in PBS
or ethanol were used for coating than when LPS-HDL com-
plexes were used. Similarly, immunopurified anti-J5 LPS hu-
man IgG or IgM had apparent cross-reactivity when free
antigens in ethanol or PBS were used for coating. Here again,
this cross-reactivity was more important for IgM than for IgG.
In contrast, when using LPS-HDL complexes for coating, im-
munopurified anti-J5 LPS IgG or IgM were exclusively
directed against J5 LPS and did not cross-react with Re LPS
or lipid A.
Antibodies measured in antisera
from rabbits immunized with Non-
immune
Antibodies, E. coli LPS E. coli rabbit
antigen J5 Re Lipid A 0111 sera
IgG
HDL-J5 LPS >2 0 0 0 0
HDL-Re LPS 0 >2 0 0 0
HDL-lipid A 0 0 >2 0 0
HDL-Ol11 LPS 0 0 0 >2 0
J5 LPS* 0.82 0.18 0 0 0
Re LPS* 0.17 0.94 0 0 0
Lipid A* 0.08 0.26 1.07 0 0
0111 LPS* 0 0.22 0 1.88 0
J5 LPSt 1.44 0.10 0.18 0 0
Re LPSt 0.11 1.42 0.26 0 0
Lipid At 0.33 0.55 >2 0 0
0111 LPSt 0 0 0.15 0.62 0
IgM
HDL-J5 LPS >2 0 0.22 0 0
HDL-Re LPS 0 1.65 0.16 0 0
HDL-lipid A 0 0.85 >2 0 0
HDL-O111 LPS 0 0 0 >2 0
J5 LPS* 1.84 0.18 0.14 0 0
Re LPS* 0.12 0.51 0.27 0 0
Lipid A* 0 0.18 0.81 0 0
0111 LPS* 0 0.53 0.11 >2 0
J5 LPSt »2 0.24 0.44 0.10 0.15
Re LPSt 0.21 1.11 0.44 0 0
Lipid At 0.21 0.70 1.22 0 0.13
0111 LPSt 0 0.34 0.42 1.89 0
NOTE. Optical densities (OD) were measured as follows: dilution of rabbit an-
tisera, I :500; dilution of conjugated antibody, I: 1000; incubation of peroxidase sub-
strate, 30 min. OD values < 0.05 are shown as O. LPS, lipopolysaccharide; HDL,
high-density lipoproteins.
* Free LPS or lipid A diluted in PBS buffer.
t Free LPS or lipid A diluted in ethanol. '
tern of reactivity of polyclonal antisera from rabbits im-
munized with E. coli J5 or E. coli 0111 whole cells, Re LPS,
or lipid A extracted from Re LPS. When free LPS in PBS
were used as antigens for coating, cross-reactions were ob-
served both with polyclonal rabbit IgG and IgM, including
cross-reactions with 0111 LPS. This apparent cross-reactivity
was increased when ethanol was used as solvent. As for mono-
clonal antibodies, when LPS-HDL were used as antigens for
coating, polyclonal rabbit IgG showed antibody specificities
exclusively directed against the corresponding immunizing
antigens. Some cross-reactivity against core LPS antigens was
observed when polyclonal rabbit IgM were tested, but no an-
tiserum to core LPS cross-reacted with the smooth 0111 LPS.
Studieswithhumanpolyclonalantibodies (table4.) Simi-
lar comparisons using various coating conditions for ELISA
were done to evaluate the pattern of reactivity of polyclonal
human IgG and IgM antibodies. We used IgG and IgM frac-
tions purified from a pool of plasma from human volunteers
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stationary-phase bacteria and might therefore differ from the
LPS harbored bybacteria during infectious processes. Indeed,
core LPS determinants may be more exposed on LPS from
growing bacteria [26] or from bacteria submitted to antibi-
otic drugs [47] than from stationary-phase bacteria.
Although the controversies about in vitro cross-reactivity
of core LPS antibodies are not resolved, recent studies with
monoclonal antibodies [29, 48] seem to support the concept
that core LPS antibodies can be cross-protective in vivo. How-
ever, the results of animal experiments in this field are sub-
ject to caution because the published data have not always
been replicated [8, 20, 49-54]. Thus, the adequate character-
ization of the binding specificities of antibodies directed against
core LPS or lipid A constitutes an important prerequisite for
the understanding of their biologic role. To detect cross-
reactive antibodies of the various immunoglobulin classes,
ELISA appears more appropriate than hemagglutination as-
says, which measure predominantly IgM antibodies, or than
.passive hemolysis assays, which cannot discriminate between
immunoglobulin classes.
We investigated various ELISA conditions, considering a
factor that has recently been emphasized, that LPS from rough
strains are hydrophobic structures that can have significant
variability of their physical properties (e.g., their degree of
hydration and state of aggregation) depending on how they
are prepared and diluted. These physical properties have a
profound impact on their biologic activities [55-57] and, at
least for lipid A, on the nonspecific binding of antibodies to
it [23].
There are at least three reasons why LPS-HDL complexes
may improve the presentation ofLPS to antibodies in ELISA.
(1) Due to the physicochemical properties of the complexes,
exposure of hydrophilic determinants would favor the bind-
ing of specific antibodies while masking the hydrophobic struc-
tures that promote nonspecific binding [23]. In addition, the
protein content of the LPS-HDL complexes could improve
the reliability of the coating of core LPS to plastic surfaces.
(2) The preparation of LPS-HDL complexes includes an
ultracentrifugation step on KBr gradient that might remove
proteins and nucleic acids that are coextracted with LPS dur-
ing the standard extraction procedures. For instance, phenol-
extracted LPS (Sigma) has a bacterial protein content of
0.5 %-3 % and a bacterial RNA content of 0.5 %-3 %. These
amounts ofcontaminants may be sufficient to cause significant
reactions with antibodies in ELISA when 10-100 p.gofLPS/ml
are used for coating, since proteins are better coating agents
than LPS. (3) HDL is an important physiologic carrier ofLPS
in serum [38, 39]: Ifcross-reactive antibodies can act as neu-
tralizing antibodies in protection against endotoxin shock, they
would recognize exposed LPS epitopes within LPS-HDL com-
plexes.
In the present experiments, when free lipid A or free core
LPS diluted in PBS buffer or in ethanol were used for coating
ELISA plates, cross-reactive bindings against core LPS or
lipid A were detected in various core LPS antisera, immuno-
globulin preparations, or monoclonal antibodies. In contrast,
when using LPS-HDL complexes as antigens, the same anti-
body preparations showed a very narrow specificity that was
restricted to the antigens used for immunization. One possi-
ble explanation for the cross-reactivity detected when using
free LPS for coating was that nonspecific binding of antibod-
ies occurred due to the exposure of the hydrophobic deepest
parts of LPS on the ELISA plates. In support of that explana-
tion was the pattern of reactivity of the monoclonal antibod-
ies, particularly of Cl17 whose precise specificity is known
in detail. The epitope of this anti-Re LPS antibody is part
of lipid A and part of the KDO disaccharide. This clone does
not recognize lipid A alone or J5 LPS [43].
The methodology used to define the specific epitope of Cl17
involved inhibition studies and gel precipitation using chem-
ically defined KDO and lipid A-derived synthetic molecules
[58]. Thus the reactivity of Cl17 to free lipid A in the present
experiments showed the apparent artifactual nature of this bind-
ing. Ofparticular relevance is our finding that when the bind-
ing of Cl17 was measured using ethanol-coated LPS or lipid
A ELISA plates, the nonspecific interaction observed between
Cl17 and lipid A was nearly the same magnitude as its specific
interaction with ReLPS. Therefore, our data demonstrate that
apparently false cross-reactivities of core LPS antibodies may
occur with standard ELISA, a phenomenon that was absent
or minimal when LPS-HDL complexes were used for coating.
A possible explanation for the lack of broad cross-reactivity
of anti-core LPS antibodies in the assay with LPS-HDL com-
plexes may be the hiding of LPS epitopes within the HDL
molecule. For Cl17, this explanation is unlikely because it
was shown by other methods that this antibody does not
specifically recognize lipid A. The observed lack of binding
of this clone to HDL-lipid A was therefore most likely due
to the abolishment of nonspecific interactions. With the other
antibodies or antisera, the possibility that epitopes were con-
cealed within HDL complexes seemed unlikely since the
specifically defined antibodies reacted fully against their cor-
responding antigens within HDL complexes. In addition, the
specific reactions were more pronounced as revealed byhigher
optical density values when using LPS-HDL complexes as
antigens than when using free LPS, perhaps because the ex-
posure of hydrophilic antigenic determinants was favored in
LPS-HDL complexes. Therefore, byanalogy with the findings
with Cl17, the apparent cross-reactivity observed when the
other antibodies were tested with free core LPS probably
resulted from nonspecific interactions.
Although we have tested only one LPS extracted from a
smooth strain, E. coli 0111, the absence of cross-reactivity
of core LPS antibodies with this LPS is of particular rele-
vance because the strain is the parent of the rough mutant
J5 and has been extensively studied in protection experiments
in animals, including in experiments with purified 0111 LPS
prepared by the same method as the LPS used in our ELISA
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[2, 48, 59-61]. Since the core LPS antibodies or antisera,
which seemed protective in vivo against 0111 LPS, did not
recognize it in vitro, the mechanisms responsible for the in
vivo protection demonstrated by others remain enigmatic.
Our data do not rule out the possibility that cross-reactivity
might be demonstrated in other systems nor do they exclude
the possibility that HDL may prevent some cross-reactive sites
from interacting with antibody. However, the present study
demonstrates that apparently artefactual cross-reactivities of
core LPS antibodies may be shown by standard ELISA and
that the use of LPS-HDL complexes as coating antigens
significantlydecreases this phenomenon. Therefore, the results
of experiments of cross-reactivities performed with ELISA
using free core LPS or lipid A as coating antigens must be
interpreted with caution. Indeed, definite proof for true cross-
reactive antilxxlies requires measurements of affinity constants
for clearly defined epitopes within the LPS molecule.
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